Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. März 2017 16:05 ET | Quelle: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results

Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...
01. September 2016 08:00 ET | Quelle: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer

REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
22. Januar 2016 08:30 ET | Quelle: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium

REDWOOD CITY, Calif., Jan. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...